Current Methods for Hyperpolarized [1-13C]pyruvate MRI Human Studies
Abstract
MRI with hyperpolarized (HP) 13C agents, also known as HP 13C MRI, can measure processes such as localized metabolism that is altered in numerous cancers, liver, heart, kidney diseases, and more. It has been translated into human studies during the past 10 years, with recent rapid growth in studies largely based on increasing availability of hyperpolarized agent preparation methods suitable for use in humans. This paper aims to capture the current successful practices for HP MRI human studies with [1-13C]pyruvate - by far the most commonly used agent, which sits at a key metabolic junction in glycolysis. The paper is divided into four major topic areas: (1) HP 13C-pyruvate preparation, (2) MRI system setup and calibrations, (3) data acquisition and image reconstruction, and (4) data analysis and quantification. In each area, we identified the key components for a successful study, summarized both published studies and current practices, and discuss evidence gaps, strengths, and limitations. This paper is the output of the HP 13C MRI Consensus Group as well as the ISMRM Hyperpolarized Media MR and Hyperpolarized Methods & Equipment study groups. It further aims to provide a comprehensive reference for future consensus building as the field continues to advance human studies with this metabolic imaging modality.
Cite
@article{arxiv.2309.04040,
title = {Current Methods for Hyperpolarized [1-13C]pyruvate MRI Human Studies},
author = {Peder EZ Larson and Jenna ML Bernard and James A Bankson and Nikolaj Bøgh and Robert A Bok and Albert P. Chen and Charles H Cunningham and Jeremy Gordon and Jan-Bernd Hövener and Christoffer Laustsen and Dirk Mayer and Mary A McLean and Franz Schilling and James Slater and Jean-Luc Vanderheyden and Cornelius von Morze and Daniel B Vigneron and Duan Xu and the HP 13C MRI Consensus Group},
journal= {arXiv preprint arXiv:2309.04040},
year = {2023}
}
Comments
Accepted at Magnetic Resonance in Medicine